BREAKING: The FDA has just approved a needle-free version of Wegovy, set to revolutionize weight loss treatment in the United States. This new oral pill, launching in January 2024, offers a more affordable option at just $149 per month, compared to the injectable version priced at approximately $1,350 monthly.
The approval marks a significant milestone as Wegovy becomes the first oral GLP-1 drug specifically designed for weight management. The pill contains semaglutide, the same active ingredient found in the injectable version, providing patients with an effective alternative that eliminates the need for weekly injections.
Novo Nordisk, the pharmaceutical company behind Wegovy, confirmed that the pill is expected to be available through pharmacies and select telehealth providers. “With today’s approval of the Wegovy pill, patients will have a convenient, once-daily option that can help them lose as much weight as the original Wegovy injection,” stated Mike Doustdar, CEO of Novo Nordisk.
Clinical trials underline its effectiveness, showing that over 300 participants lost an average of 16.6% of their body weight over approximately 64 weeks. This result is comparable to the weight loss achieved with the injectable version.
The pill is intended for adults suffering from obesity or those who are overweight and have at least one weight-related health condition. Additionally, it has been approved to mitigate the risk of serious cardiovascular events such as heart attacks and strokes in certain patients.
As the demand for GLP-1 weight-loss medications continues to surge, a recent survey from the health policy research group KFF revealed that about 12% of Americans are currently using drugs like Wegovy or Ozempic for weight loss or chronic conditions—an increase of six percentage points in 18 months. However, many users express concerns over affordability, with approximately half reporting challenges in paying for these medications even with insurance.
Novo Nordisk has indicated that further details regarding coverage and savings options for higher doses and eligible patients will be shared closer to the launch date. This development is likely to have a profound impact on millions seeking effective weight management solutions.
Stay tuned for updates as Wegovy transitions into this new form, potentially changing the landscape of weight loss treatment in the United States.
